Lilly Puts On A Happy Face, But Will Investors Buy In?
Executive Summary
It was all about the pipeline during Eli Lilly's fourth quarter earnings call, as company execs strove to convince analysts they can compensate for revenue losses from big-ticket products about to lose patent protection
You may also be interested in...
FDA Recommends Genetic Testing For Plavix, Opens Window For Effient
FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient
FDA Recommends Genetic Testing For Plavix, Opens Window For Effient
FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient
FDA Recommends Genetic Testing For Plavix Response, Opens Window For Effient
FDA increased the level of its Plavix warning for slow metabolizers to a black box, recommending genetic testing and advising health care professionals to consider using other anti-platelet medications or alternative dosing strategies.